<DOC>
<DOCNO>EP-0626173</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Aerosol composition containing fusafungine
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P3104	A61K900	A61K4500	A61K3566	A61K4706	A61K4706	A61K912	A61K900	A61K3566	A61K4500	A61K912	A61P2900	A61P2900	A61P3100	A61K	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61K	A61P	A61P	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P31	A61K9	A61K45	A61K35	A61K47	A61K47	A61K9	A61K9	A61K35	A61K45	A61K9	A61P29	A61P29	A61P31	A61K	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Novel medicinal aerosol composition (formulation) based on fusafungine, comprising an excipient chosen from dimethylisosorbide or preferably isopropyl myristate and using 1,1,1,2-tetrafluoroethane as the propellent.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
ADIR
</APPLICANT-NAME>
<APPLICANT-NAME>
ADIR ET COMPAGNIE
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
CUINE ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
MORISSEAU SERGE
</INVENTOR-NAME>
<INVENTOR-NAME>
CUINE, ALAIN
</INVENTOR-NAME>
<INVENTOR-NAME>
MORISSEAU, SERGE
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Pharmaceutical composition in aerosol form comprising 
as sole ingredients an active ingredient: fusafungine, 

an excipient selected from isopropyl myristate and 
dimethyl isosorbide, and a propellant: 1,1,1,2-tetrafluoroethane, 

or propellant 134a. 
Pharmaceutical composition according to claim 1 in 
which the excipient is isopropyl myristate. 
Pharmaceutical composition according to claim 1 in 
which fusafungine is present in an amount of between 0.01 

and 5 % of the total weight of the formulation. 
Pharmaceutical composition according to claim 1 in 
which 1,1,1,2-tetrafluoroethane is present in an amount 

of between 55 and 95 % of the total weight of the 
formulation. 
Pharmaceutical composition according to claim 2 in 
which isopropyl myristate is present in an amount of 

between 10 and 40 % of the total weight of the formulation. 
Pharmaceutical composition according to claim 2 which 
is : 


fusafungine : 50 mg 
isopropyl myristate quantity sufficient for : 5 ml 
propellant 134a : 15 ml. 
Pharmaceutical composition according to claim 1 in 
which the excipient is dimethyl isosorbide.  

 
Pharmaceutical composition according to claim 7 which 
is : 


fusafungine : 50 mg 
dimethyl isosorbide quantity sufficient for : 5 ml 
propellant 134a : 15 ml. 
Pharmaceutical specialty intended for the administration 
of fusafungine to a patient by the oral or nasal 

route, comprising an aerosol container fitted with a dose 
dispensing valve, the aerosol container containing a 

pharmaceutical composition according to any one of 
claims 1 to 7. 
A process for the preparation of a pharmaceutical 
specialty which comprises filling an aerosol container 

with a pharmaceutical composition according to any one 
of claims 1 to 7 and fitting the aerosol container with 

a dose dispensing valve. 
</CLAIMS>
</TEXT>
</DOC>
